Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | CFTR | P13569 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31515143 | 0.93 | GAA (0.53) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL857214 | 0.86 | CFTR (0.60) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL24413993 | 0.85 | CFTR (0.58) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL9793695 | 0.85 | GAA (0.59) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL19328721 | 0.84 | GAA (0.72) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL7762378 | 0.84 | ABL1 (0.61) | GAACFTRABL1NQO2KDM4E | |
| SCHEMBL2849661 | 0.84 | CFTR (0.45) | GAACFTRABL1NQO2ALDH1A1 | |
| SCHEMBL1817672 | 0.82 | CA1 (0.51) | GAAKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL17239556 | 0.81 | CFTR (0.43) | GAACFTRABL1ALDH1A1MAPT | |
| SCHEMBL7948445 | 0.81 | NR4A2 (0.46) | GAACFTRABL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4103558-A1 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| EP-3307730-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-24 | — | — | EP | disclosed |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-6228868-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-08 | — | — | US | disclosed |
| WO-2000006556-A1 | SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS | ABBOTT LABORATORIES (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | GAA 4278/4885CFTR 1057/4885ABL1 1340/4885 |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAPK4 | GAA 4841/4885CFTR 4773/4885ABL1 58/4885 |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | GAA 3863/4885CFTR 3945/4885ABL1 432/4885 |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | MAPK1, MAPKAPK2, MAPKAPK5 | GAA 4776/4885CFTR 4821/4885ABL1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.